KZR - NASDAQ
Kezar Life Sciences, Inc.
$7.29
+0.0000%Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live SnapshotKezar Life Sciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Kezar Life Sciences, Inc. Balance Sheet
KZR • NASDAQ
| Kezar Life Sciences, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
71.9M | 41.7M | 35.5M | 40.5M | 62.9M | 21.2M | 15M | 24.2M | 51M | 9.7M | |
0.0 | 90.5M | 165.9M | 236.1M | 145.5M | 119.2M | 63.3M | 83.3M | 0.0 | 0.0 | |
71.9M | 132.2M | 201.4M | 276.6M | 208.4M | 140.4M | 78.2M | 107.4M | 51M | 9.7M | |
1.9M | 424K | 2.3M | 0.0 | 0.0 | 766K | 642K | 0.0 | 0.0 | 0.0 | |
1.7M | 0.0 | 1.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
184K | 424K | 695K | 0.0 | 0.0 | 766K | 642K | 0.0 | 0.0 | 0.0 | |
535K | 4.5M | 3M | 9.2M | 2.6M | 2.7M | 1.9M | 1.9M | 785K | 142K | |
1.4M | 351K | 251K | 0.0 | 729K | 865K | 406K | 489K | 508K | 598K | |
75.7M | 137.5M | 207M | 285.7M | 211.7M | 144.8M | 81.1M | 109.8M | 52.3M | 10.5M | |
NON-CURRENT ASSETS | ||||||||||
915K | 4.8M | 8.7M | 13.2M | 6M | 6.7M | 8.1M | 4.6M | 1.5M | 862K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13K | 13K | |
0.0 | 2.4M | 5.6M | 674K | 282K | 282K | 282K | 282K | 343K | 62K | |
915K | 7.2M | 14.3M | 13.8M | 6.3M | 7M | 8.4M | 4.9M | 1.9M | 937K | |
76.6M | 144.7M | 221.2M | 299.6M | 217.9M | 151.8M | 89.5M | 114.7M | 54.2M | 11.4M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
507K | 3.7M | 8.3M | 2.5M | 2M | 2.4M | 823K | 193K | 547K | 466K | |
507K | 3.7M | 8.3M | 2.5M | 2M | 2.4M | 823K | 193K | 547K | 466K | |
66K | 2.7M | 3.7M | 3.3M | 3M | 1.4M | 1.3M | 736K | 422K | 134K | |
2.3M | 5.2M | 3M | 0.0 | 0.0 | 1M | 900K | 0.0 | 0.0 | 0.0 | |
0.0 | 3.5M | 0.0 | 2.6M | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.7M | 5.2M | 2.8M | 2.7M | 2M | 1.7M | 3M | 2.4M | 515K | 51K | |
6.6M | 20.3M | 17.7M | 11M | 8.2M | 6.4M | 6M | 3.3M | 1.5M | 651K | |
NON-CURRENT LIABILITIES | ||||||||||
0.0 | 5.1M | 10.1M | 9.8M | 9.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.5M | 78.4M | 28.2M | |
0.0 | 7.4M | 15.9M | 18.7M | 12.8M | 4.4M | 5.5M | 2.5M | 78.4M | 28.2M | |
0.0 | 5.9M | 5.9M | 11.4M | 4.4M | 4.4M | 5.5M | 0.0 | 0.0 | 0.0 | |
6.6M | 27.8M | 33.7M | 29.7M | 21.1M | 10.9M | 11.5M | 5.9M | 79.9M | 28.9M | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -451K | -232K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 77.9M | 28.2M | |
7K | 7K | 73K | 68K | 56K | 46K | 19K | 19K | 1K | 1K | |
560.6M | 551.6M | 538.4M | 519.6M | 377.8M | 267.1M | 162.5M | 158.2M | 451K | 232K | |
-490.5M | -434.5M | -350.8M | -248.9M | -180.7M | -126M | -84.3M | -49.2M | -26M | -17.5M | |
0.0 | -162K | -130K | -923K | -291K | -137K | -196K | -203K | -111K | -150K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -77.5M | -27.9M | |
70.1M | 116.9M | 187.6M | 269.9M | 196.9M | 141M | 78M | 108.8M | -25.7M | -17.4M | |
70.1M | 116.9M | 187.6M | 269.9M | 196.9M | 141M | 78M | 108.8M | -25.7M | -17.4M | |
SUMMARY | ||||||||||
76.6M | 144.7M | 221.2M | 299.6M | 217.9M | 151.8M | 89.5M | 114.7M | 54.2M | 11.4M | |
0.0 | 90.5M | 165.9M | 236.1M | 145.5M | 119.2M | 63.3M | 83.3M | 13K | 13K | |
2.3M | 16.2M | 18.9M | 21.3M | 14M | 5.5M | 6.4M | 0.0 | 0.0 | 0.0 | |
-69.6M | -25.6M | -16.6M | -19.2M | -48.8M | -15.8M | -8.6M | -24.2M | -51M | -9.7M | |
7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 | 7,323,156 |
SEC Filings
KZR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 11, 2026 | May 08, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your KZR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.